SURF - サ―フェイス・オンコロジ― (Surface Oncology Inc.) サ―フェイス・オンコロジ―

 SURFのチャート


 SURFの企業情報

symbol SURF
会社名 Surface Oncology Inc (サ―フェイス・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Surface Oncology Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system to block the activity of a range of suppressor cells in the tumor microenvironment and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity it hopes to expand the reach of cancer immunotherapy to patients in need of treatment.   サ―フェイス・オンコロジ―は米国のバイオ医薬品企業。臨床段階で、がん治療における免疫療法の開発に従事する。免疫抑制腫瘍微小環境における専門知識を、がん治療の開発に用いる。同社候補薬はタンパク質を標的とするSRF231、CD73を阻害するSRF373、インタ―ロイキンを標的とするSRF388などである。本社所在地はマサチュ―セッツ州ケンブリッジ。   Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
本社所在地 50 Hampshire Street 8th Floor Cambridge MA 02139 USA
代表者氏名 Daniel S. Lynch ダニエルS.リンチ
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 617-714-4096
設立年月日 41730
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 56人
url www.surfaceoncology.com
nasdaq_url https://www.nasdaq.com/symbol/surf
adr_tso
EBITDA EBITDA(百万ドル) -15.23000
終値(lastsale) 9.08
時価総額(marketcap) 250739324.04
時価総額 時価総額(百万ドル) 231.96150
売上高 売上高(百万ドル) 52.88200
企業価値(EV) 企業価値(EV)(百万ドル) 46.40750
当期純利益 当期純利益(百万ドル) -21.92600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Surface Oncology Inc revenues increased from $7.9M to $47.9M. Net income applicable to common stockholders totaled $8.3M vs. loss of $15.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest and other income (expense) net increase from $262K to $900K (income).

 SURFのテクニカル分析


 SURFのニュース

   Surface Oncology Inc. Shares Close the Week 23.1% Higher - Weekly Wrap  2021/03/12 22:30:00 Kwhen Finance
Surface Oncology Inc. shares closed this week 23.1% higher than it did at the end of last week. The stock is currently down 0.1% year-to-date, up 315.8% over the past 12 months, and down 30.8% over the past five years. This week, the Dow Jones Industrial Average rose 4.1%, and the S&P 500 rose 2.7%. Trading Activity Shares traded as high as $9.33 and as low as $7.14 this week.Shares closed 4e+1% below its 52-week high and 6e+2% above its 52-week low.Trading volume this week was 10.4% lower than the 10-day average and 15.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -100.2% The company's stock price performance over the past 12 months beats the peer average by 153.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Surface Oncology Inc. Shares Close the Day 12.4% Higher - Daily Wrap  2021/03/09 22:30:00 Kwhen Finance
Surface Oncology Inc. shares closed today 12.4% higher than it did at the end of yesterday. The stock is currently down 20.3% year-to-date, up 158.2% over the past 12 months, and down 44.8% over the past five years. Today, the Dow Jones Industrial Average rose 0.1%, and the S&P 500 rose 1.4%. Trading Activity Shares traded as high as $9.23 and as low as $6.54 this week.Shares closed 4e+1% below its 52-week high and 5e+2% above its 52-week low.Trading volume this week was 21.7% lower than the 10-day average and 13.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -163.3% The company's stock price performance over the past 12 months beats the peer average by 156.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Surface Oncology Inc. Shares Close the Day 11.0% Lower - Daily Wrap  2021/02/18 22:30:00 Kwhen Finance
Surface Oncology Inc. shares closed today 11.0% lower than it did at the end of yesterday. The stock is currently up 13.2% year-to-date, up 217.9% over the past 12 months, and down 21.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $11.93 and as low as $9.30 this week.Shares closed 4e+1% below its 52-week high and 6e+2% above its 52-week low.Trading volume this week was 5.4% higher than the 10-day average and 10.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -84.6% The company's stock price performance over the past 12 months beats the peer average by 58.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Surface Oncology Inc. Shares Close the Day 12.4% Higher - Daily Wrap  2021/02/08 22:30:00 Kwhen Finance
Surface Oncology Inc. shares closed today 12.4% higher than it did at the end of yesterday. The stock is currently up 20.9% year-to-date, up 266.2% over the past 12 months, and down 16.2% over the past five years. Today, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.7%. Trading Activity Shares traded as high as $11.25 and as low as $10.20 this week.Shares closed 9% below its 52-week high and 8e+2% above its 52-week low.Trading volume this week was 22.8% lower than the 10-day average and 35.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date lags the peer average by -70.2% The company's stock price performance over the past 12 months beats the peer average by 122.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Surface Oncology Inc. Shares Climb 3.0% Past Previous 52-Week High - Market Mover  2021/01/20 22:30:00 Kwhen Finance
Surface Oncology Inc. shares closed 3.0% higher than its previous 52 week high, giving the company a market cap of $545M. The stock is currently up 45.2% year-to-date, up 298.2% over the past 12 months, and up 0.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.0%. Trading Activity Trading volume this week was 14.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 22.8% The company's stock price performance over the past 12 months beats the peer average by 166.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa  2021/01/22 12:22:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Merus NV (NASDAQ: MRUS ) Neuronetics Inc (NASDAQ: STIM ) OncoSec Medical Inc (NASDAQ: ONCS ) (announced common stock offering) PRA Health Sciences Inc (NASDAQ: PRAH ) Precision BioSciences Inc (NASDAQ: DTIL ) Profound Medical Corp (NASDAQ: PROF ) Renalytix AI PLC (NASDAQ: RNLX ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Surface Oncology Inc (NASDAQ: SURF ) Syneos Health Inc (NASDAQ: SYNH ) Synlogic Inc (NASDAQ: SYBX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.
   CULTIVATED: Inside the rise and fall of Civilized — An uphill battle for Black cannabis entrepreneurs — Legal cannabis and coronavirus  2020/07/17 13:37:00 Business Insider
Welcome to Cultivated, our weekly newsletter where we're bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar global cannabis boom. Sign up here to get it in your inbox every week . If you want a discount to BI Prime to read our stories, sign up here! Happy Friday readers, We're back after a two-week hiatus. The East Coast saw a nice run of summer swell, so my vacation was perfectly timed to take in some (surf)board meetings. Prior to my vacation, I spent a few weeks talking to former employees and investors about what happened at Civilized , a cannabis media and events company that quietly laid off all of its employees after a takeover offer fell through. In the span of a little more than a year, the company's CEO, Derek Riedle, went from flying on private jets with celebrities to laying off employees without severance pay. Civilized's rise and fall is perhaps emblematic of what happened in the past two years in the cannabis industry, where the promise of a new multibillion-dollar industry met a more subdued reality, and greed got in the way of responsible decisionmaking.
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa  2021/01/22 12:22:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Merus NV (NASDAQ: MRUS ) Neuronetics Inc (NASDAQ: STIM ) OncoSec Medical Inc (NASDAQ: ONCS ) (announced common stock offering) PRA Health Sciences Inc (NASDAQ: PRAH ) Precision BioSciences Inc (NASDAQ: DTIL ) Profound Medical Corp (NASDAQ: PROF ) Renalytix AI PLC (NASDAQ: RNLX ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Surface Oncology Inc (NASDAQ: SURF ) Syneos Health Inc (NASDAQ: SYNH ) Synlogic Inc (NASDAQ: SYBX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.
   CULTIVATED: Inside the rise and fall of Civilized — An uphill battle for Black cannabis entrepreneurs — Legal cannabis and coronavirus  2020/07/17 13:37:00 Business Insider
Welcome to Cultivated, our weekly newsletter where we're bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar global cannabis boom. Sign up here to get it in your inbox every week . If you want a discount to BI Prime to read our stories, sign up here! Happy Friday readers, We're back after a two-week hiatus. The East Coast saw a nice run of summer swell, so my vacation was perfectly timed to take in some (surf)board meetings. Prior to my vacation, I spent a few weeks talking to former employees and investors about what happened at Civilized , a cannabis media and events company that quietly laid off all of its employees after a takeover offer fell through. In the span of a little more than a year, the company's CEO, Derek Riedle, went from flying on private jets with celebrities to laying off employees without severance pay. Civilized's rise and fall is perhaps emblematic of what happened in the past two years in the cannabis industry, where the promise of a new multibillion-dollar industry met a more subdued reality, and greed got in the way of responsible decisionmaking.
   Stock Alert: Surface Oncology Shares Up 36% In Premarket  2020/05/20 09:11:00 RTT News
Shares of Surface Oncology (SURF) are up over 36% in pre-market today, after the company announced that it has entered into a clinical trial collaboration with Merck (MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States.
   Analysis on Impact of COVID-19-Subsea Umbilicals, Risers, and Flow Lines Market 2020-2024 | Surge in Energy Demand to Boost Growth | Technavio  2020/05/14 01:15:00 Benzinga Feeds
Technavio has been monitoring the subsea umbilicals, risers, and flow lines market and it is poised to grow by USD 1.35 billion during 2020-2024, progressing at a CAGR of almost 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005672/en/ Technavio has announced its latest market research report titled Global Subsea Umbilicals, Risers, and Flow Lines (SURF) Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. ABB Ltd., Aker Solutions ASA, Baker Hughes Co., Dril-Quip Inc., National Oilwell Varco Inc., Oceaneering International Inc., Prysmian Spa, Saipem Spa, Schlumberger Ltd., and TechnipFMC Plc are some of the major market participants.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サ―フェイス・オンコロジ― SURF Surface Oncology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)